Show simple item record

dc.contributor.authorNegi, Neema
dc.contributor.authorGriffin, Matthew D.
dc.date.accessioned2021-01-04T14:01:21Z
dc.date.available2021-01-04T14:01:21Z
dc.date.issued2020-01-29
dc.identifier.citationNegi, Neema, & Griffin, Matthew D. (2020). Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance. STEM CELLS, 38(5), 596-605. doi:https://doi.org/10.1002/stem.3151en_IE
dc.identifier.issn1066-5099
dc.identifier.urihttp://hdl.handle.net/10379/16397
dc.description.abstractThe immunomodulatory potential of mesenchymal stromal cells (MSCs) and regulatory T cells (T-reg) is well recognized by translational scientists in the field of regenerative medicine and cellular therapies. A wide range of preclinical studies as well as a limited number of human clinical trials of MSC therapies have not only shown promising safety and efficacy profiles but have also revealed changes in T-reg frequency and function. However, the mechanisms underlying this potentially important observation are not well understood and, consequently, the optimal strategies for harnessing MSC/T-reg cross-talk remain elusive. Cell-to-cell contact, production of soluble factors, reprogramming of antigen presenting cells to tolerogenic phenotypes, and induction of extracellular vesicles ("exosomes") have emerged as possible mechanisms by which MSCs produce an immune-modulatory milieu for T-reg expansion. Additionally, these two cell types have the potential to complement each other's immunoregulatory functions, and a combinatorial approach may exert synergistic effects for the treatment of immunological diseases. In this review, we critically assess recent translational research related to the outcomes and mechanistic basis of MSC effects on T-reg and provide a perspective on the potential for this knowledge base to be further exploited for the treatment of autoimmune disorders and transplants.en_IE
dc.description.sponsorshipThis publication has emanated from research conducted with the financial support of Science Foundation Ireland (SFI) and is co‐funded under the European Regional Development Fund under Grant Number 13/RC/2073. It has also received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska‐Curie grant agreement No 713690 (NN and MDG). MDG is additionally supported by grants from the European Commission [Horizon 2020 Collaborative Health Project NEPHSTROM (grant number 634086) and FP7 Collaborative Health Project VISICORT (grant number 602470)], from Science Foundation Ireland [REMEDI Strategic Research Cluster (grant number 09/SRC/B1794)] and the European Regional Development Fund.en_IE
dc.formatapplication/pdfen_IE
dc.language.isoenen_IE
dc.publisherAlphaMed Press and Wileyen_IE
dc.relation.ispartofStem Cells (Dayton, Ohio)en
dc.subjectLEUKEMIA INHIBITORY FACTORen_IE
dc.subjectVERSUS-HOST-DISEASEen_IE
dc.subjectSTEM-CELLSen_IE
dc.subjectDENDRITIC CELLSen_IE
dc.subjectPROSTAGLANDIN E-2en_IE
dc.subjectEXTRACELLULAR VESICLESen_IE
dc.subjectANTIINFLAMMATORY PHENOTYPEen_IE
dc.subjectLIVER-TRANSPLANTATIONen_IE
dc.subjectACUTE REJECTIONen_IE
dc.subjectTREG CELLSen_IE
dc.titleEffects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevanceen_IE
dc.typeArticleen_IE
dc.date.updated2020-12-19T17:25:25Z
dc.identifier.doi10.1002/stem.3151
dc.local.publishedsourcehttps://doi.org/10.1002/stem.3151en_IE
dc.description.peer-reviewedpeer-reviewed
dc.contributor.funderScience Foundation Irelanden_IE
dc.contributor.funderEuropean Regional Development Funden_IE
dc.contributor.funderHorizon 2020en_IE
dc.contributor.funderSeventh Framework Programmeen_IE
dc.internal.rssid20952281
dc.local.contactMatthew Dallas Griffin, Remedi, Biomedical Sciences Buil, Corrib Village, Dangan, Nui Galway. 5436 Email: matthew.griffin@nuigalway.ie
dc.local.copyrightcheckedYes
dc.local.versionACCEPTED
dcterms.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Centres/13/RC/2073/IE/C�RAM - Centre for Research in Medical Devices/en_IE
dcterms.projectinfo:eu-repo/grantAgreement/EC/H2020::MSCA-COFUND-FP/713690/EU/Career Development and Mobility Fellowships in Medical Device Research and Development: A CÚRAM Industry-Academia Training Initiative./MedTrainen_IE
dcterms.projectinfo:eu-repo/grantAgreement/EC/H2020::RIA/634086/EU/Novel Stromal Cell Therapy for Diabetic Kidney Disease/NEPHSTROMen_IE
dcterms.projectinfo:eu-repo/grantAgreement/EC/FP7::SP1::HEALTH/602470/EU/Adverse Immune Signatures and their Prevention in Corneal Transplantation/VISICORTen_IE
dcterms.projectinfo:eu-repo/grantAgreement/SFI/SFI Strategic Research Cluster/09/SRC/B1794/IE/SRC REMEDI: REMEDI-2: From Research to Human Therapy/en_IE
nui.item.downloads1


Files in this item

Attribution-NonCommercial-NoDerivs 3.0 Ireland
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. Please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.

The following license files are associated with this item:

Thumbnail

This item appears in the following Collection(s)

Show simple item record